Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TV46017 in Healthy Volunteers and COPD Patients
NCT02315131Phase 1Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Mar 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of TV-46017 in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Forced Expiratory Volume in 1 Second Area Under the Curve from 0 to 12 hours. Started Mar 2015; status: terminated.
02
Drugs
TV-46017
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02315131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315131.